Bosh sahifaLSTA • NASDAQ
add
Lisata Therapeutics Inc
Yopilish kursi
2,90 $
Kunlik diapazon
2,86 $ - 2,88 $
Yillik diapazon
2,05 $ - 3,83 $
Bozor kapitalizatsiyasi
24,36 mln USD
Oʻrtacha hajm
15,91 ming
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | — | — |
Joriy xarajat | 5,34 mln | -10,53% |
Sof foyda | -4,93 mln | 6,29% |
Sof foyda marjasi | — | — |
Har bir ulushga tushum | -0,59 | 9,23% |
EBITDA | -5,29 mln | 10,53% |
Amaldagi soliq stavkasi | — | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 35,86 mln | -34,08% |
Jami aktivlari | 38,20 mln | -34,24% |
Jami passivlari | 4,76 mln | -11,55% |
Umumiy kapital | 33,44 mln | — |
Tarqatilgan aksiyalar | 8,39 mln | — |
Narxi/balansdagi bahosi | 0,72 | — |
Aktivlardan daromad | -33,03% | — |
Kapitaldan daromad | -37,14% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -4,93 mln | 6,29% |
Operatsiyalardan naqd pul | -2,52 mln | 29,72% |
Sarmoyadan naqd pul | -6,30 mln | -151,46% |
Moliyadan naqd pul | 0,00 | 100,00% |
Naqd pulning sof oʻzgarishi | -8,78 mln | -200,53% |
Boʻsh pul | -857,00 ming | 47,89% |
Haqida
Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through the acquisition of Cend Therapeutics by Caladrius Biosciences in September 2022.
In April 2024 the FDA granted their product, certepetide, orphan drug status. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide. Wikipedia
Tashkil etilgan
1980
Sayt
Xodimlar soni
25
